|Education||BS, North Carolina State University|
|Current Position||Research Scientist|
National Center for Advancing Translational Sciences (NCATS)
Drug Screens in Glioblastoma Stem Cells”
Glioblastoma Multiforme (GBM) is a malignant astrocytic brain tumor most common in adults. It is one of the most lethal cancers given that the median survival time for patients following treatment is approximately 15 months. The current standard of care therapy is surgical resection of the tumor followed by concurrent radiation plus Temezolomide. New therapies are being tested yet most do not increase overall survival time. My project is focused on screening new compounds and drug libraries that can be add to current therapy to improve the prognosis for glioblastoma patients.